Get to Know Dr. Sean Dineen
Dineen has extensive experience in the novel combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, also known as HIPEC.
The combination has revolutionized the way several peritoneal diseases are being treated today while extending survival times dramatically.
Complete cytoreduction is designed to remove all visible disease throughout the abdominal cavity. The HIPEC procedure, which uses a heated chemotherapy solution, involves the killing of any microscopic tumor cells that may have evaded the surgeon.
Dineen led a recent multicenter clinical study confirming that major organ removal to achieve a more complete tumor resection of mesothelioma did not increase severe complications, but often improved long-term survival outcomes.
“You go into the surgery knowing the operation may be extensive, but you always try to balance the extent of the surgery with the benefit the patient will receive from it,” he said.
Dineen is part of the Department of Gastrointestinal Oncology at Moffitt. His research focuses on how tumors and the local environment interact to promote metastatic disease, and the ways to combat it.
Specialties of Dr. Sean Dineen
- Peritoneal mesothelioma
- Liver cancer
- Pancreatic cancer
- Appendiceal cancer
- Esophageal cancer
- Colorectal cancer
- HIPEC procedure
Dr. Sean Dineen’s Experience and Medical Education
- H. Lee Moffitt Cancer Center
- University of Kentucky Markey Cancer Center
- MD Anderson Cancer Center (Fellowship)
- University of Texas Southwestern (Residency)
- University of Louisville Medical School (M.D.)
Awards and Certifications
- American Board of Surgical Oncology
- American Board of Surgery
- American College of Surgeons
- Society for Surgeons of the Alimentary Tract
Publications of Dr. Sean Dineen
- Lee, R.M. et al. (2021, January). A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. Journal of Surgical Oncology.
- Kubi, B. et al. (2021, January). Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis. Annals of Surgical Oncology.
- Leiting, J.L et al. (2020, October). The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative. International Journal of Hyperthermia.
- Eng, O.S. et al. (2020, July). Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. Journal of Surgical Oncology.
Thank you for your feedback. Would you like to speak with a Patient Advocate?